Endoplasmic Reticulum Stress Nano‐Orchestrators for Precisely Regulated Immunogenic Cell Death as Potent Cancer Vaccines
Source abstract
Abstract
Abstract Dying tumor cells regulated by immunogenic cell death (ICD) inducers are promising candidates for cancer vaccine development because of their comprehensive antigen spectrum. However, their limited immunogenicity and potential tumorigenicity hinder clinical translation. To address these challenges, a nano‐orchestrator is developed that targets the endoplasmic reticulum (ER) stress, a critical pre‐ICD event, to optimize the “precise dose” of ER stress. Using a clinical‐range irradiation fluence (50‒200 J cm−2) with an 808 nm laser, the release of damage associated molecular patterns (DAMPs) and antigens are precisely regulated. A fluence of 150 J cm−2 (2 W cm−2 for 75 s) increases dendritic cell maturation and antitumor T cell proliferation, providing valuable clinical insights. The ER stress nano‐orchestrator enhances both adjuvanticity and antigenicity via the protein kinase R‐like endoplasmic reticulum kinase (PERK)‐C/EBP homologous protein (CHOP) pathway to regulate ICD‐induced DAMPs and promote tumor cell apoptosis. These optimized ER stress phototherapeutic dying tumor cells can serve as prophylactic vaccines, achieving a remarkable 100% success rate against tumor rechallenge in vivo. Additionally, the nano‐orchestrator shows the potential to develop in situ therapeutic tumor vaccines when combined with anti‐PD‐L1 treatment, providing important insights into enhancing the efficacy of immune checkpoint regulators by modulating endogenous immune responses.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Phagocytosis and Immune Regulation · Endoplasmic Reticulum Stress and Disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System School of Pharmaceutical Sciences Peking University Beijing 100191 China
Drug Clinical Trial Center Peking University Third Hospital Peking University Beijing 100191 China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Beijing Municipality
References (59)
Show source-provided references
1. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
2. 10.1038/nri.2017.13110.1038/nri.2017.131 ↗
3. 10.1002/advs.20230012110.1002/advs.202300121 ↗
4. 10.1038/s41416-023-02327-610.1038/s41416-023-02327-6 ↗
5. 10.1126/sciadv.aba402410.1126/sciadv.aba4024 ↗
6. 10.1038/s41590-022-01132-210.1038/s41590-022-01132-2 ↗
7. 10.1016/j.copbio.2020.06.00710.1016/j.copbio.2020.06.007 ↗
8. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
9. 10.1016/j.chom.2014.02.00310.1016/j.chom.2014.02.003 ↗
10. 10.1038/emboj.2011.49710.1038/emboj.2011.497 ↗
11. 10.1038/s41577-019-0215-710.1038/s41577-019-0215-7 ↗
12. 10.1038/s41577-018-0117-010.1038/s41577-018-0117-0 ↗
13. 10.1038/nri221610.1038/nri2216 ↗
14. 10.1007/s00262-011-1184-210.1007/s00262-011-1184-2 ↗
15. 10.1016/j.trecan.2017.07.00210.1016/j.trecan.2017.07.002 ↗
16. 10.1038/s41568-020-00312-210.1038/s41568-020-00312-2 ↗
17. 10.1038/nrc380010.1038/nrc3800 ↗
18. 10.1038/ncb273810.1038/ncb2738 ↗
19. 10.7554/eLife.5229110.7554/eLife.52291 ↗
20. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
21. 10.1021/acsnano.2c0166910.1021/acsnano.2c01669 ↗
22. 10.1038/cdd.2013.4810.1038/cdd.2013.48 ↗
23. 10.1016/j.jconrel.2023.05.04410.1016/j.jconrel.2023.05.044 ↗
24. 10.3390/cells1118289910.3390/cells11182899 ↗
25. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
26. 10.1021/acsnano.0c0224910.1021/acsnano.0c02249 ↗
27. 10.1016/j.biomaterials.2020.12064810.1016/j.biomaterials.2020.120648 ↗
28. 10.1021/acsnano.3c1314310.1021/acsnano.3c13143 ↗
29. 10.1016/j.ccell.2022.08.01610.1016/j.ccell.2022.08.016 ↗
30. 10.1038/s41419-021-04318-y10.1038/s41419-021-04318-y ↗
31. 10.1136/jitc-2020-00124310.1136/jitc-2020-001243 ↗
32. 10.1038/s41590-019-0433-y10.1038/s41590-019-0433-y ↗
33. 10.1111/pcmr.1211110.1111/pcmr.12111 ↗
34. 10.1126/scitranslmed.300380710.1126/scitranslmed.3003807 ↗
35. 10.1038/emboj.2012.210.1038/emboj.2012.2 ↗
36. 10.1002/adma.20220570110.1002/adma.202205701 ↗
37. 10.1038/s41420-019-0214-210.1038/s41420-019-0214-2 ↗
38. 10.1002/wsbm.159510.1002/wsbm.1595 ↗
39. 10.1038/cdd.2012.7410.1038/cdd.2012.74 ↗
40. 10.1089/pho.2015.397910.1089/pho.2015.3979 ↗
41. 10.1007/s10103-011-0887-010.1007/s10103-011-0887-0 ↗
42. 10.1002/adma.20210484910.1002/adma.202104849 ↗
43. 10.1021/jm801546k10.1021/jm801546k ↗
44. 10.1038/nprot.2008.21110.1038/nprot.2008.211 ↗
45. 10.1093/nar/gkn92310.1093/nar/gkn923 ↗
46. 10.1016/j.molp.2020.06.00910.1016/j.molp.2020.06.009 ↗
47. 10.1016/j.immuni.2006.08.01710.1016/j.immuni.2006.08.017 ↗
48. 10.1038/nrm295210.1038/nrm2952 ↗
49. 10.1016/j.jconrel.2022.11.05310.1016/j.jconrel.2022.11.053 ↗
50. 10.1038/nmat482210.1038/nmat4822 ↗
51. 10.1016/j.nantod.2021.10135610.1016/j.nantod.2021.101356 ↗
52. 10.1016/j.apsb.2021.11.00510.1016/j.apsb.2021.11.005 ↗
53. 10.1002/advs.20200214710.1002/advs.202002147 ↗
54. 10.1016/j.cytogfr.2013.05.00110.1016/j.cytogfr.2013.05.001 ↗
55. 10.1038/3501401410.1038/35014014 ↗
56. 10.1002/adfm.20190896110.1002/adfm.201908961 ↗
57. 10.1016/j.cell.2017.08.02710.1016/j.cell.2017.08.027 ↗
58. 10.1002/advs.20220760810.1002/advs.202207608 ↗
59. 10.1002/smll.20220720110.1002/smll.202207201 ↗